On 11/7/23, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) stock enjoyed a major increase of 12.2%, closing at $85.49. Relative to the market the stock has been weak over the last nine months but has risen 5.6% during the last week.
Current PriceTarget Research Rating
BMRN is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Biomarin Pharmaceutical has a current Value Trend Rating of D (Negative). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Biomarin Pharmaceutical has a slightly negative Appreciation Score of 40 and a poor Power Rating of 28, triggering the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment